Nivolumab/Hyaluronidase

纳武利尤单抗/透明质酸酶

Report date: 2026/05/26 20:00:28

Base Information

Drug NameNivolumab/Hyaluronidase
Drug Alias NameNivolumab/Hyaluronidase-nvhyNivolumab/vorhyaluronidase alfaOPDIVO QVANTIGOpdivo QvantigONO-4538HSC
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionProgrammed cell death protein 1 inhibitorsHyaluronic acid modulators
TargetsProgrammed cell death protein 1Hyaluronic acid
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungStomach Neoplasms +[11] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms +[9] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/12/27
Country/TerritoryCzechiaUnited StatesPoland +[20] 
CombinationsYes Nivolumab
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb CompanyOno Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyBristol-Myers Squibb CompanyOno Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungStomach Neoplasms +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A